Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Manages osteoarthritis pain. ANDA 209487, held by Lupin. Meloxicam.
As of Nov 14, 2026, ANDA 209487 (Meloxicam), held by Lupin, was first approved by FDA on Jun 1, 2020, with 2 approved supplements and 0 published complete response letters.
First approved: Jun 1, 2020
Review: Standard
Supplements approved: 2
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Meloxicam capsules are indicated for management of osteoarthritis pain. Meloxicam capsule is a non-steroidal anti-inflammatory drug indicated for management of osteoarthritis (OA) pain.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
